Nature Communications (Sep 2018)
Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer
- Alex H. Wagner,
- Siddhartha Devarakonda,
- Zachary L. Skidmore,
- Kilannin Krysiak,
- Avinash Ramu,
- Lee Trani,
- Jason Kunisaki,
- Ashiq Masood,
- Saiama N. Waqar,
- Nicholas C. Spies,
- Daniel Morgensztern,
- Jason Waligorski,
- Jennifer Ponce,
- Robert S. Fulton,
- Leonard B. Maggi,
- Jason D. Weber,
- Mark A. Watson,
- Christopher J. O’Conor,
- Jon H. Ritter,
- Rachelle R. Olsen,
- Haixia Cheng,
- Anandaroop Mukhopadhyay,
- Ismail Can,
- Melissa H. Cessna,
- Trudy G. Oliver,
- Elaine R. Mardis,
- Richard K. Wilson,
- Malachi Griffith,
- Obi L. Griffith,
- Ramaswamy Govindan
Affiliations
- Alex H. Wagner
- McDonnell Genome Institute, Washington University School of Medicine
- Siddhartha Devarakonda
- Division of Oncology, Department of Medicine, Washington University School of Medicine
- Zachary L. Skidmore
- McDonnell Genome Institute, Washington University School of Medicine
- Kilannin Krysiak
- McDonnell Genome Institute, Washington University School of Medicine
- Avinash Ramu
- McDonnell Genome Institute, Washington University School of Medicine
- Lee Trani
- McDonnell Genome Institute, Washington University School of Medicine
- Jason Kunisaki
- McDonnell Genome Institute, Washington University School of Medicine
- Ashiq Masood
- Division of Oncology, Department of Medicine, Washington University School of Medicine
- Saiama N. Waqar
- Division of Oncology, Department of Medicine, Washington University School of Medicine
- Nicholas C. Spies
- McDonnell Genome Institute, Washington University School of Medicine
- Daniel Morgensztern
- Division of Oncology, Department of Medicine, Washington University School of Medicine
- Jason Waligorski
- McDonnell Genome Institute, Washington University School of Medicine
- Jennifer Ponce
- McDonnell Genome Institute, Washington University School of Medicine
- Robert S. Fulton
- McDonnell Genome Institute, Washington University School of Medicine
- Leonard B. Maggi
- Division of Oncology, Department of Medicine, Washington University School of Medicine
- Jason D. Weber
- Division of Oncology, Department of Medicine, Washington University School of Medicine
- Mark A. Watson
- Alvin J Siteman Cancer Center, Washington University
- Christopher J. O’Conor
- Department of Pathology and Immunology, Washington University School of Medicine
- Jon H. Ritter
- Department of Pathology and Immunology, Washington University School of Medicine
- Rachelle R. Olsen
- Department of Oncological Sciences, University of Utah, Huntsman Cancer Institute
- Haixia Cheng
- Department of Oncological Sciences, University of Utah, Huntsman Cancer Institute
- Anandaroop Mukhopadhyay
- Department of Oncological Sciences, University of Utah, Huntsman Cancer Institute
- Ismail Can
- Department of Oncological Sciences, University of Utah, Huntsman Cancer Institute
- Melissa H. Cessna
- Intermountain Healthcare BioRepository and Department of Pathology, Intermountain Healthcare
- Trudy G. Oliver
- Department of Oncological Sciences, University of Utah, Huntsman Cancer Institute
- Elaine R. Mardis
- McDonnell Genome Institute, Washington University School of Medicine
- Richard K. Wilson
- McDonnell Genome Institute, Washington University School of Medicine
- Malachi Griffith
- McDonnell Genome Institute, Washington University School of Medicine
- Obi L. Griffith
- McDonnell Genome Institute, Washington University School of Medicine
- Ramaswamy Govindan
- Division of Oncology, Department of Medicine, Washington University School of Medicine
- DOI
- https://doi.org/10.1038/s41467-018-06162-9
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 11
Abstract
Small cell lung cancer (SCLC) patients frequently relapse and become resistant to chemotherapy. Here, the authors analyse the genomic and transcriptomic landscape of primary and relapsed SCLC patients as well as in vitro models, and discover that activation of WNT signalling can drive chemotherapy resistance.
